NextGen Invitro Diagnostics is a molecular diagnostics startup based in Gurugram, India (some sources say New Delhi), that develops affordable infectious disease tests, notably for tuberculosis, for healthcare providers.

This Startup Deep Dive explains what NextGen Invitro Diagnostics does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

NextGen Invitro Diagnostics in Brief

• What it is: NextGen Invitro Diagnostics is an Indian Infectious disease diagnostics company based in Gurugram (some sources say New Delhi).
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• The company works on molecular diagnostics and microfluidics platforms for affordable, accurate diagnosis of infectious diseases.
• Its best-known product is TB-LAMP, developed by Eiken (Japan) and marketed by Germany-based Human Diagnostics, with NextGen as exclusive marketing partner in India.
• It received approval for COVSCAN qPCR-96, a multiplex RT-PCR test, and for an antigen test; a serology-based TB test was in clinical validation and a 'Fever Panel' for four fevers in one 15-minute test was near launch (2021).
• Funding: Rs 18.5 crore invested (reported, 2021), plus BIRAC and USISTEF grants.

NextGen Invitro Diagnostics Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is NextGen Invitro Diagnostics?

NextGen Invitro Diagnostics operates in the Infectious disease diagnostics space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to NextGen Invitro Diagnostics.

• The company works on molecular diagnostics and microfluidics platforms for affordable, accurate diagnosis of infectious diseases.
• Its best-known product is TB-LAMP, developed by Eiken (Japan) and marketed by Germany-based Human Diagnostics, with NextGen as exclusive marketing partner in India.
• It received approval for COVSCAN qPCR-96, a multiplex RT-PCR test, and for an antigen test; a serology-based TB test was in clinical validation and a 'Fever Panel' for four fevers in one 15-minute test was near launch (2021).
• Seven or eight TB-LAMP installations across hospitals and clinics were reported in 2021.

The Origin Story of NextGen Invitro Diagnostics

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Dr. Pravin Kini, Varun Chopra, Sushil Mehta.
• Incorporated on 26 April 2015 by Dr Pravin Kini, Varun Chopra and Sushil Mehta (Chairman); other names listed in profiles include Srinivas Aluri Rao, TV Rajan, Ameet Desai and Ashok Jain, though whether they are founders or investors is unclear.
• The founding team had almost three decades of combined healthcare industry experience.
• Incubated at DBT-supported facilities C-CAMP and BBB Bionest; funded by investors and key management employees, with BIRAC and USISTEF grants.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Infectious disease diagnostics sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• 26 April 2015: incorporated.
• WHO endorsed LAMP-based TB testing in August 2016; NextGen launched TB-LAMP in India with Human Diagnostics.
• ICMR approval to commercialise TB-LAMP in the private market (undated listing).
• 2020-21: COVSCAN qPCR-96 RT-PCR test and antigen test approved.
• 2021: Rs 73 crore revenue since inception and team of 30 (company-stated).

NextGen Invitro Diagnostics Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• Rs 18.5 crore invested as of a 2021 profile (reported), from investors and key management employees, plus a small bank working-capital line.
• Grants from BIRAC and USISTEF; no grant amounts found.
• Looking to raise money in 2021 for a manufacturing facility and R&D expansion.

How Does NextGen Invitro Diagnostics Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• Sells diagnostic test kits and reagents, with a manufacturing facility that the company says holds ISO 9001, ISO 13485 and ISO 14001 standards.
• Cost approach: multiplexing and easier sample collection such as dried blood spots, claimed to cut cost about 40% versus sequential testing.
• Distribution partnership with Human Diagnostics for TB-LAMP.

The Numbers: NextGen Invitro Diagnostics Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• Revenue since inception of Rs 73 crore (company-stated, 2021 profile); no fiscal-year breakdown found.
• Team of 30 in 2021 (10 R&D, 10 commercial, 10 support); another listing gives 22 employees and $500K trailing revenue, which may not be comparable.
• Company aimed for about Rs 100 crore revenue within 4-5 years (to about 2025).

Market Opportunity for NextGen Invitro Diagnostics

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• Focus is tuberculosis and other infectious disease diagnosis in India; addressable market about Rs 3,000 crore excluding COVID diagnostics (company-stated).
• The company cited smear microscopy as roughly 50% accurate and pitched molecular tests as the improvement, in line with the government goal of a TB-free India by 2025.

Technology and Product at NextGen Invitro Diagnostics

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• Molecular diagnostics (LAMP, RT-PCR), multiplexing and microfluidics, with point-of-care devices in development.
• TB-LAMP uses a DNA extraction method with high specificity and sensitivity and low turnaround time (company-stated).

Team and Culture at NextGen Invitro Diagnostics

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Co-founders reported as Dr. Pravin Kini, Varun Chopra and Sushil Mehta, who is Chairman.
• Team of about 30 in 2021.

NextGen Invitro Diagnostics Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

Risks and Challenges for NextGen Invitro Diagnostics

• Headcount and revenue figures differ across sources and dates, so current scale is unclear; most data is from 2021.
• Competes against WHO-endorsed platforms from Molbio and Cepheid with strong public-sector presence.
• Manufacturing build-out and further funding were still pending as of the latest data found.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

NextGen Invitro Diagnostics Growth Outlook: What to Watch

• Plans in 2021 included expanding R&D, building a manufacturing facility, a pan-India push, and reaching PHC/CHC levels.
• Target was about Rs 100 crore revenue by around 2025; progress was not found.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether NextGen Invitro Diagnostics can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where NextGen Invitro Diagnostics Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for NextGen Invitro Diagnostics

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for NextGen Invitro Diagnostics.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from NextGen Invitro Diagnostics

Studying a company in the Infectious disease diagnostics space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about NextGen Invitro Diagnostics.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate NextGen Invitro Diagnostics as a Startup

• Customer clarity: Can NextGen Invitro Diagnostics name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

NextGen Invitro Diagnostics is part of India’s growing Infectious disease diagnostics ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

NextGen Invitro Diagnostics FAQs: Frequently Asked Questions

What is NextGen Invitro Diagnostics?

NextGen Invitro Diagnostics is a molecular diagnostics startup based in Gurugram, India (some sources say New Delhi), that develops affordable infectious disease tests, notably for tuberculosis, for healthcare providers. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded NextGen Invitro Diagnostics?

NextGen Invitro Diagnostics was founded by Dr. Pravin Kini, Varun Chopra, Sushil Mehta, and the company reports a founding year of 2015 (incorporated 26 April 2015).

How much funding has NextGen Invitro Diagnostics raised?

Rs 18.5 crore invested (reported, 2021), plus BIRAC and USISTEF grants. Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does NextGen Invitro Diagnostics make money?

NextGen Invitro Diagnostics earns revenue from its Infectious disease diagnostics products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of NextGen Invitro Diagnostics?

Reported rivals include Molbio Diagnostics, Cepheid (GeneXpert). See the competitor comparison above for how they differ.

What are the main risks for NextGen Invitro Diagnostics?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Avail Finance — Avail Finance: lending to India’s blue-collar workforce | Onnes Cryogenics — short profile of what is publicly known. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.